The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Will Be The Estimated Market Size Of The Viral Vector Contract Development And Manufacturing Organization (CDMO) Market By 2030?
The market size for viral vector contract development and manufacturing organizations (CDMOs) has experienced significant expansion in recent years. It is forecast to grow from $1.47 billion in 2025 to $1.7 billion in 2026, at a compound annual growth rate (CAGR) of 15.6%. The historical growth of this market can be attributed to a growing clinical pipeline of gene therapies, early outsourcing of viral vector production, expansion of academic research collaborations, limited in-house manufacturing capabilities of biotech firms, and increasing regulatory approvals for viral vectors.
The viral vector contract development and manufacturing organization (cdmo) market size is anticipated to experience substantial growth over the coming years. It is projected to reach $3.01 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 15.3%. This expansion during the forecast period can be attributed to the escalating commercialization of gene and cell therapies, increased investments in specialized viral vector facilities, a surging demand for scalable manufacturing platforms, the broadening of global CDMO partnerships, and innovations in high-yield vector production technologies. Key trends during this timeframe involve the enlargement of capacity for large-scale viral vector output, the heightened adoption of single-use manufacturing processes, a burgeoning requirement for comprehensive CDMO offerings, an elevated focus on regulatory-compliant cGMP facilities, and the improved integration of sophisticated analytical methods in vector fabrication.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=29238&type=smp
What Influential Factors Are Boosting The Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Demand?
The increasing financial commitment towards gene therapy investigations is projected to stimulate expansion within the viral vector contract development and manufacturing organization (CDMO) market in the future. Gene therapy research aims to discover methods to modify or control genes within human cells to rectify genetic conditions or address a range of illnesses. Funding for gene therapy research is rising due to its potential to offer lasting or permanent solutions for genetic diseases that were previously incurable, attracting significant attention from both healthcare innovators and investors. Viral vector CDMOs support gene therapy research by providing specialized expertise and sophisticated manufacturing capabilities for producing high-quality viral vectors, which are essential for the secure and efficient transfer of therapeutic genes. For instance, in July 2025, according to the Office for Life Sciences, a UK-based government department, the government has committed up to $800 million (£600 million) to develop one of the world’s most advanced, secure, and AI-compatible health data platforms, integrating genomic, diagnostic, and clinical information at a population level to transform NHS and broader healthcare data into a hub for global research trials and AI investment. Consequently, the expanding investment in gene therapy research is a key factor propelling the growth of the viral vector contract development and manufacturing organization (CDMO) market.
Which Segment Divisions Form The Structure Of The Viral Vector Contract Development And Manufacturing Organization (CDMO) Market?
The viral vector contract development and manufacturing organization (cdmo) market covered in this report is segmented –
1) By Service Type: Process Development, Manufacturing, Analytical Testing, Fill-Finish, Other Service Types
2) By Vector Type: Adenoviral Vectors, Lentiviral Vectors, Adeno-Associated Viral Vectors, Retroviral Vectors, Other Vector Types
3) By Workflow: Upstream Manufacturing, Downstream Manufacturing
4) By Application: Gene Therapy, Vaccines, Cell Therapy, Other Applications
5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Process Development: Upstream Process Development, Downstream Process Development, Analytical Development, Process Characterization
2) By Manufacturing: Clinical Manufacturing, Commercial Manufacturing, cGMP Manufacturing, Cell Bank Production, Fill-Finish Services
3) By Analytical Testing: Release Testing, Stability Testing, Bioassays, Characterization Studies, Regulatory Compliance Testing
4) By Fill-Finish: Aseptic Filling, Lyophilization, Final Packaging, Cold Chain Management, Labeling And Serialization
5) By Other Service Types: Regulatory Support, Supply Chain Management, Technology Transfer, Clinical Trial Support, Cold Chain Logistics
What Trends Are Influencing The Viral Vector Contract Development And Manufacturing Organization (CDMO) Market?
Leading firms within the viral vector contract development and manufacturing organization (CDMO) market are prioritizing the creation of sophisticated offerings, particularly AAV manufacturing solutions, to ensure production can be scaled and remains consistent. AAV manufacturing solutions encompass specific methods and systems crafted for the effective production of safe and potent adeno-associated virus vectors essential for gene therapy. As an illustration, in August 2025, ProBio, a US-based contract development and manufacturing organization (CDMO), introduced cGMP Adeno-Associated Virus (AAV) manufacturing services at its cutting-edge 128,000 sq. ft. facility in Hopewell, New Jersey. This expansion is designed to meet the increasing demand for high-quality viral vector production while underscoring ProBio’s dedication to fostering the development of innovative gene therapies. The Hopewell site was specifically built to deliver comprehensive AAV manufacturing solutions, adhering to international regulatory and quality benchmarks. ProBio’s service portfolio now encompasses fully integrated capabilities such as GMP plasmid DNA production, AAV vector manufacturing, and final drug product formulation with aseptic fill/finish, all consolidated within a single U.S. location. This unified strategy improves coordination, minimizes process transfers, and accelerates timelines throughout the entire drug development lifecycle.
Who Are The Firms Contributing To The Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Ecosystem?
Major companies operating in the viral vector contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec, Samsung Biologics Co. Ltd., FUJIFILM Biotechnologies, Oxford Biomedica Plc, Hillgene, Takara Bio Inc., SkyPharma Production SAS, GeneScript ProBio, Obio Technology Corp. Ltd., VectorBuilder, Charles River Laboratories Pvt. Ltd., Creative Biogene, Esco Aster Pte. Ltd., Genesail Biotech Co. Ltd., CEVEC Pharmaceuticals, Cell and Gene Therapy Catapult, CoJourney, Applied Biological Laboratories Inc.
Access The Complete Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Report:
Which Regional Market Leads The Viral Vector Contract Development And Manufacturing Organization (CDMO) Market?
North America was the largest region in the viral vector contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=29238&type=smp
Browse Through More Reports Similar to the Global Viral Vector Contract Development And Manufacturing Organization (CDMO) Market 2026, By The Business Research Company
Viral Vector Manufacturing Market Report 2026
https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report
Viral And Non Viral Vector Manufacturing Market Report 2026
Oral Expectorant Market Report 2026
https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model